

1 **An epithelial microRNA upregulates airway IL-25 and TSLP expression in type 2-high**  
2 **asthma via targeting CD39-extracellular ATP axis**

3

4 **Kan Zhang<sup>1,2,3\*</sup>, Yuchen Feng<sup>1,2\*</sup>, Yuxia Liang<sup>1,2</sup>, Wenliang Wu<sup>1,2</sup>, Chenli Chang<sup>1,2</sup>, Dian**  
5 **Chen<sup>1,2</sup>, Shengchong Chen<sup>1,2</sup>, Jiali Gao<sup>1,2</sup>, Gongqi Chen<sup>1,2</sup>, Lingling Yi<sup>1,2</sup>, Dan Cheng<sup>4</sup>,**  
6 **Guohua Zhen<sup>1,2,†</sup>**

7 <sup>1</sup>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji  
8 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,  
9 China; <sup>2</sup>Key Laboratory of Respiratory Diseases, National Health Commission of People's  
10 Republic of China, and National Clinical Research Center for Respiratory Diseases, Wuhan, China;  
11 <sup>3</sup>Department of Respiratory and Critical Care Medicine, The Affiliated Suzhou Hospital of  
12 Nanjing Medical University, Suzhou, China; <sup>4</sup>Department of Respiratory and Critical Care  
13 Medicine, Renmin Hospital of Wuhan University, Wuhan, China.

14

15 \* KZ and YF contributed equally to this work.

16 †**Correspondence to:** Guohua Zhen, Division of Respiratory and Critical Care Medicine, Tongji  
17 Hospital, Wuhan, China 430030; Email: ghzhen@tjh.tjmu.edu.cn

18

19 **Short title:** MicroRNA 206 upregulates IL-25 and TSLP in asthma

20

21 **ABSTRACT:**

22 **Introduction:** Epithelial cell-derived cytokines IL-25, IL-33 and TSLP initiate type 2  
23 inflammation in allergic diseases. However, the signaling pathway regulating these cytokines  
24 expression remains elusive. We examined the role of epithelial microRNAs in the expression of  
25 IL-25, IL-33 and TSLP in asthma.

26 **Methods:** Differentially expressed epithelial microRNAs between type 2-low and type 2-high  
27 asthma patients were identified using microarray. The expression of microRNA (miR)-206, its  
28 target CD39, CD39's substrate ATP, and IL-25, IL-33, TSLP were measured in epithelial brushings  
29 and bronchoalveolar lavage fluid from both asthma subsets and healthy controls. The links  
30 between these measurements were functionally validated in vitro and in vivo.

31 **Results:** MiR-206 was the most highly expressed microRNA in type 2-high asthma relative to  
32 type 2-low asthma, but was downregulated in both asthma subsets compared with healthy controls.  
33 CD39, an ecto-nucleotidase degrading ATP, was a target of miR-206 and upregulated in asthma.  
34 Allergen-induced acute extracellular ATP accumulation led to miR-206 downregulation and CD39  
35 upregulation in human bronchial epithelial cells, forming a feedback loop to eliminate excessive  
36 ATP. Airway ATP levels strongly correlated with elevated IL-25 and TSLP expression in type  
37 2-high asthma patients. Intriguingly, airway miR-206 antagonism increased Cd39 expression,  
38 reduced ATP accumulation, suppressed Il-25, Il-33, Tslp expression and group 2 innate lymphoid  
39 cells expansion, and alleviated type 2 inflammation in a mouse model of asthma. However, airway  
40 miR-206 overexpression had opposite effects.

41 **Conclusion:** Together, epithelial miR-206 upregulates airway IL-25, TSLP expression via  
42 targeting CD39-extracellular ATP axis, which represents a novel therapeutic target in type 2-high

43 asthma.

44

45 **Keywords:** asthma; epithelial cells; microRNA; CD39; extracellular ATP; IL-25; TSLP

46

## 47 INTRODUCTION

48 Asthma is a heterogeneous disease with different phenotypes, endotypes, and variable responses  
49 to management approaches [1, 2]. A prominent endotype of asthma is the presence of type 2  
50 inflammation [3, 4]. Airway epithelial cells play pivotal roles in the initiation of type 2  
51 inflammation by expressing interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP)  
52 [5-7]. These epithelial cell-derived cytokines act on innate immune cells including dendritic cells,  
53 group 2 innate lymphoid cells (ILC2s) and mast cells [8-15]. Recent identification of memory Th2  
54 cells with high expression of receptor for IL-25, IL-33 and TSLP supports a role of these  
55 cytokines in adaptive immune responses in allergy [16, 17]. IL-25 [18, 19], IL-33 [20], and TSLP  
56 [11] have each been reported to be indispensable and sufficient for type 2 cytokine production,  
57 eosinophilic airway inflammation and AHR in certain mouse models. In human asthma, various  
58 expression patterns of these cytokines have been reported [21-25]. Although IL-25, IL-33 and  
59 TSLP are critical in type 2 airway inflammation, the upstream signaling pathway regulating their  
60 expression remains elusive.

61 When exposed to environmental stimuli, airway epithelial cells rapidly express danger signals  
62 such as adenosine triphosphate (ATP), uric acid to alert the immune system [26, 27]. Allergen  
63 exposure enhanced airway ATP concentration in human asthma and sensitized mice. Neutralizing  
64 airway ATP or blocking of purine signaling suppressed airway inflammation in allergen sensitized  
65 and challenged mice [28]. Extracellular ATP concentration is tightly controlled by ecto-nucleoside  
66 triphosphate diphosphohydrolases (ENTPD) [29]. CD39 (encoded by *ENTPDI*), catalyzing the  
67 degradation of extracellular ATP and ADP, is expressed in airway epithelial cells [30]. Inhibition  
68 of CD39 activity increased BALF ATP concentration and intensified ovalbumin-induced

69 bronchospasm in mice [31]. CD39-deficient mice exhibited worsened airway inflammation and  
70 mucus overproduction after allergen sensitization and challenge [32], whereas the paradoxically  
71 alleviated airway inflammation was also reported in CD39-deficient mice [33]. Recently, it is  
72 reported that ATP serves as a sensor for an airborne allergen to trigger IL-33 release in airway  
73 epithelial cells [34]. Together, these studies suggest that CD39-extracellular ATP axis may regulate  
74 IL-25, IL-33 and TSLP in asthma.

75 MicroRNAs (miRNAs) regulate gene expression by promoting the catabolism of the target  
76 transcripts as well as attenuating their translation. There are a growing body of evidence that  
77 miRNAs play important roles in epithelial cell, ILC2 and Th2 cell differentiation and function in  
78 asthma [35-38]. MiR-19a promotes IL-5, IL-13 expression in ILC2s and Th2 cells [37, 38]. Let-7  
79 miRNA regulates IL-13 expression and allergic airway inflammation [39, 40]. The global  
80 miRNAs expression in airway epithelial cells are altered in asthma [36, 41]. However, the  
81 difference of epithelial miRNA expression between type 2-low and type 2-high asthma remains  
82 unknown. We hypothesized that the differentially expressed epithelial miRNAs between the two  
83 asthma subsets may contribute to IL-25, IL-33 and TSLP expression in asthma.

84 In this study, we profiled the epithelial miRNAs' expression in type 2-low and -high asthma  
85 patients. We found that miR-206, the most highly expressed miRNA in type 2-high asthma relative  
86 to type 2-low asthma, targets CD39-extracellular ATP axis to regulate IL-25 and TSLP expression  
87 in cultured bronchial epithelial cells. Airway ATP levels were increased and strongly correlated  
88 with elevated IL-25 and TSLP expression in type 2-high asthma patients. In a mouse model of  
89 asthma, manipulation of airway miR-206 expression altered IL-25, IL-33, Tslp expression, ILC2  
90 expansion, and type 2 airway inflammation.

## 92 MATERIAL AND METHODS

### 93 Human subjects

94 We recruited 26 healthy control subjects and 57 asthma patients who were symptomatic, newly  
95 diagnosed and treatment-naïve. All subjects were Chinese and were recruited from Tongji Hospital.  
96 Subjects with asthma were diagnosed by a physician; had symptoms of episodic cough, wheeze  
97 and/or dyspnea; and had accumulated dosage of methacholine provoking a 20% fall (PD<sub>20</sub>) of  
98 forced expiratory volume in the first second (FEV<sub>1</sub>) < 2.505 mg and/or ≥12% increase in FEV<sub>1</sub>  
99 following inhalation of 200μg salbutamol. We recruited subjects who had never smoked or  
100 received inhaled or oral corticosteroid or leukotriene antagonist. Healthy control subjects had no  
101 respiratory symptoms, normal spirometric value and methacholine PD<sub>20</sub> ≥ 2.505 mg.

102 For each subject, we recorded demographic information, performed spirometry, measured  
103 fractional exhaled nitric oxide (FeNO), collected induced sputum and BALF samples. We  
104 performed bronchoscopy with endobronchial epithelial brushing. Brushing techniques was  
105 described previously [42].

### 106 MicroRNA microarray

107 Total RNA from bronchial epithelial brushing samples from four type 2-low and four type  
108 2-high asthma patients were extracted using TRIzol (Invitrogen). After passing RNA quantity  
109 measurement using the NanoDrop 1000, the samples were labeled using the miRCURY Hy3/Hy5  
110 power labeling kit (Exiqon) and hybridized on miRCURY LNA microRNA array (7th generation,  
111 miRBase v18; Exiqon). The slides were scanned using Axon GenePix 4000B microarray scanner  
112 (Axon Instruments). Scanned images were then imported into GenePix Pro 6.0 software (Axon  
113 Instruments) for grid alignment and data extraction. We used median normalization method to

114 obtain “normalized data”. Normalized data = (foreground - background) / median. In comparison,  
115 genes with greater than 2-fold change and statistically significant difference between two groups  
116 were considered to be differentially expressed.

### 117 **HBE cell culture and treatment**

118 Human bronchial epithelial (HBE) cells collected from healthy donors (n = 8) by bronchial  
119 brushing technique were cultured at an air-liquid interface as previously described [43, 44].  
120 Briefly, ten sites of the subsegmental bronchi of right middle and lower lobes were brushed. The  
121 dissociated cells were recovered by vortexing the brush in ice-cold DMEM. The cells were  
122 centrifuged, resuspended, then seeded into six-well plate coated with collagen I from rat tail  
123 (Corning) and grown in bronchial epithelial cell medium (BEpiCM; ScienCell) with supplements.  
124 Medium was changed every 48 h until cells were 90% confluent. Cells were then seeded on 1.1  
125 cm<sup>2</sup> Transwell inserts (Corning) with 0.4 μm pores. Cells were submerged for the first 7 days in  
126 BEpiCM (ScienCell) with supplements, and then the apical medium was removed to establish an  
127 air-liquid interface that was maintained for the next 14 days. The basolateral medium was changed  
128 to differentiation medium containing a 1:1 mixture of DMEM (Hyclone) and bronchial epithelial  
129 cell growth medium (BEGM; Lonza) with supplements and 50 nM all-trans retinoic acid  
130 (Sigma-Aldrich). Cells were stimulated with HDM (50 μg/ml; Greer Laboratories) and transfected  
131 with control or miR-206 mimic, control or miR-206 inhibitor (RiboBio), scrambled or CD39  
132 siRNA, empty or CD39 cDNA expression vector. Cells were also stimulated with HDM with or  
133 without apyrase, ATPγS (Sigma-Aldrich).

### 134 **Mouse model of allergic airway inflammation**

135 The model was established by HDM sensitization and challenge. Briefly, female C57BL/6 mice

136 received intraperitoneal injection with 100 $\mu$ l of the solution of lyophilized HDM extract (0.1  
137 mg/ml; Greer Laboratories) and Al (OH)<sub>3</sub> as an adjuvant on days 0, 7 and 14, and received 40 $\mu$ l  
138 HDM solution (3 mg/ml) or saline intranasally on days 21, 22, and 23. MiR-206 agomir (5 nmol  
139 in 40 $\mu$ l saline; RiboBio) or control agomir, or miR-206 antagomir (20 nmol in 40 $\mu$ l saline) or  
140 control antagomir were administered intranasally on days 20 and 22. Twenty-four hours after the  
141 last HDM challenge, respiratory resistance in response to a range of concentrations of intravenous  
142 acetylcholine was measured using the forced oscillation technique with the FlexiVent system  
143 (SCIREQ) as previously described [45].

#### 144 **Assessment of mouse airway inflammation**

145 Cell counts for macrophages, eosinophils, lymphocytes, and neutrophils in bronchoalveolar lavage  
146 fluid were performed as previously described [45]. Paraffin-embedded 5- $\mu$ m lung sections were  
147 stained with hematoxylin and eosin. The severity of peribronchial inflammation was scored by a  
148 blinded observer using the following features: 0, normal; 1, few cells; 2, a ring of inflammatory  
149 cells 1 cell layer deep; 3, a ring of inflammatory cells 2–4 cells deep; 4, a ring of inflammatory  
150 cells of >4 cells deep.

#### 151 **Immunohistochemistry**

152 Sections of mice lungs were stained with rabbit polyclonal CD39 (ENTPD1) antibody  
153 (Proteintech). Antibodies were detected using the Real EnVision detection system (Dako  
154 Diagnostics) according to instructions.

#### 155 **PAS staining**

156 Mice lung sections were stained with periodic acid-schiff (PAS) (Goodbio Technology) for  
157 detection of mucus. The number of PAS-staining-positive cells was counted in four random fields

158 for each lung section at  $\times 200$  magnification.

### 159 **Quantitative polymerase chain reaction (PCR)**

160 For quantification of hsa-miR-206 in epithelial brushings and HBE cells, mmu-miR-206  
161 expression in mouse lungs, *CD39*, *IL-25*, *IL-33* (transcript without exons 3, 4), *TSLP* (long  
162 isoform), *CLCA1*, *POSTN*, *SERPINB2* mRNA expression in epithelial brushings, and *Cd39*  
163 mRNA expression in mouse lungs, total RNA was isolated and reverse transcribed. Quantitative  
164 PCR were performed using an ABI Prism 7500 HT Fast Real-time PCR System (Applied  
165 Biosystems). The cycle threshold (Ct) of each gene transcript was normalized to the Ct of U6, or  
166 U48 for miRNA, and to  $\beta$ -actin or GAPDH for mRNA, respectively. Relative gene expression was  
167 calculated by using the  $2^{(-\Delta\Delta Ct)}$  method [46]. The transcript levels of each gene are  
168 expressed as relative to the median of healthy control subjects or the mean of control group and  
169  $\log_2$  transformed. Primers for quantitative PCR were listed in Supplementary Table. The  
170 stem-loop RT primer (ssD809230234), forward primer (ssD809230926) and reverse primer  
171 (ssD089261711) for hsa-/ mmu-miR-206 were from RiboBio. Taqman primer and probe sets for  
172 *IL-25* (Hs00224471\_m1), *TSLP* (long isoform; Hs01572933\_m1), and *ACTB* (Hs99999903\_m1)  
173 were from Applied Biosystems. The transcripts for *IL-33* without exons 3, 4 were determined by  
174 RNase H-dependent quantitative RT-PCR as reported by Gordon et al [47].

### 175 **In situ hybridization**

176 We performed in situ hybridization of mmu-miR-206 on paraffin-embedded sections using  
177 mmu-miR-206 miRCURY LNA miRNA detection probe (Qiagen). The sequence of the probes for  
178 mmu-miR-206 was 5'- CCACACACTTCCTTACATTCCA -3'.

### 179 **Luciferase activity assay**

180 Vector harboring wild-type, mutant CD39 3'-UTR or no 3'-UTR (control) were co-transfected  
181 with miR-206 mimic or nontargeting control into BEAS-2B cells. Luciferase activity was detected  
182 by dual luciferase reporter assay system (Promega). Normalized relative light units represent  
183 firefly luciferase activity / renilla luciferase activity.

#### 184 **Western blotting**

185 CD39 protein expression in cells was detected by monoclonal mouse-anti-human CD39 antibody  
186 (clone OTI2B10, OriGene Technologies) using Western blotting as previously described [45].

#### 187 **ELISA**

188 Human IL-25 (RayBiotech), IL-33, TSLP (R&D Systems) in supernatant from BALF and cell  
189 culture medium, and mouse Il-4, Il-5, Il-13 (R&D Systems), Il-25, Il-33 (Thermo Fisher  
190 Scientific), Tslp (R&D Systems) in BALF supernatant were measured by ELISA according to the  
191 manufacturer's instructions. Mouse plasma IgE levels were determined by ELISA (Dakewe  
192 Biotech. All samples and standards were measured in duplicate.

#### 193 **ATP measurements**

194 To measure ATP levels in human BALF, ice-cold BALF samples were centrifuged at 4°C  
195 immediately after collection and the supernatants were stored at -80°C. Supernatant of fresh mice  
196 BALF and cell culture medium were analyzed immediately. ATP levels were measured using ATP  
197 assay kit (Beyotime Biotechnology) according to instructions.

#### 198 **Flow cytometry**

199 To analyze lung ILC2s, single cell suspensions of mouse lung tissue were incubated with cocktail  
200 of biotin-conjugated monoclonal antibodies for lineage markers [CD5, CD11b, CD45R (B220),  
201 Anti-Gr-1 (Ly-6G/C), 7-4, and Ter-119], and then mixed with Anti-Biotin MicroBeads (Miltenyi

202 Biotec). Lineage-negative lung cells were isolated with column placed in the magnetic field of a  
203 MACS Separator (Miltenyi Biotec). Lineage-negative cells were stained with BV421-conjugated  
204 Live/Dead Fixable Dead Cell Stain (Invitrogen), PerCP/Cy5.5-conjugated CD25 (clone PC61;  
205 Biolegend), PE-conjugated CD127 (clone A7R34; Biolegend), FITC-conjugated T1/ST2 (clone  
206 DJ8; MD bioscience), APC-conjugated Sca-1 (clone D7; Biolegend). The samples were analyzed  
207 using EPICS-XL MCL flow cytometer (Beckman Coulter). Live lineage-negative  
208 CD25+CD127+T1/ST2+Sca-1+ lymphocytes were identified as ILC2s. Data were analyzed with  
209 FlowJo software (TreeStar).

## 210 **Statistics**

211 We analyzed data using Prism version 5 (GraphPad Software) and SPSS version 19 (SPSS  
212 Inc.). For normally distributed data, we calculated means  $\pm$  standard deviation (SD) and used  
213 parametric tests (unpaired Student's *t* test or one-way ANOVA with Bonferroni's post hoc test).  
214 For non-normally distributed data, we calculated medians (with interquartile ranges) and used  
215 non-parametric tests (Mann-Whitney test or one-way ANOVA with Bonferroni's post hoc test).  
216 We analyzed correlation using Spearman's rank order correlation. Values of  $P < 0.05$  were  
217 considered statistically significant.

## 218 **Study approvals**

219 Human and mouse studies were approved by the ethics committee of Tongji Hospital, Tongji  
220 Medical College, Huazhong University of Science and Technology. Participants gave informed  
221 consent.

222

223

224 **RESULTS**

225 **Differentially expressed epithelial miRNAs including miR-206 between type 2-low and –high**  
226 **asthma.**

227 We profiled the miRNA expression of bronchial epithelial brushings from type 2-low asthmatics  
228 ( $n = 4$ ), type 2-high asthmatics ( $n = 4$ ) using miRNA microarray. The type 2 status of asthma was  
229 defined by the expression of the type 2 signature genes (*CLCA1*, *POSTN*, and *SERPINB10*) in the  
230 epithelial brushings as previously reported [3, 48]. We found that 20 miRNAs were significantly  
231 differentially expressed between the two subsets of asthma (Figure 1A). The data are available at  
232 GEO (<http://www.ncbi.nlm.nih.gov/geo/>, accession number GSE142237). Of note, miR-206 was  
233 the most highly expressed miRNA in type 2-high asthma relative to type 2-low asthma. Several  
234 other differentially expressed miRNAs including miR-31-5p, miR-146a-5p, miR-146b-5p,  
235 miR-221-3p have been implicated in asthma pathogenesis [49-51]. Epithelial miR-221-3p  
236 expression was shown to be associated with airway eosinophilia and the expression of type 2  
237 signature genes in asthma patients in our previous study [52].

238 We next examined the expression of miR-206 in a cohort including type 2-low asthmatics ( $n =$   
239  $20$ ), type 2-high asthmatics ( $n = 37$ ), and healthy controls ( $n = 26$ ) using quantitative PCR.  
240 Compared with type 2-low asthmatics, type 2-high asthmatics had lower methacholine PD<sub>20</sub>,  
241 higher eosinophil counts in induced sputum and blood, higher fractional exhaled nitric oxide  
242 (FeNO) and serum IgE levels (Table 1). Consistent with the microarray data, epithelial miR-206  
243 expression was higher in type 2-high asthma relative to type 2-low asthma. However, compared to  
244 healthy controls, epithelial miR-206 transcript levels were decreased in both type 2-low and type  
245 2-high asthma (Figure 1B). Our data suggest that epithelial miR-206 expression is downregulated

246 in asthma and associates with airway type 2 inflammation.

247 **The expression of CD39, a target of miR-206, is upregulated in airway epithelial cells in**  
248 **asthma**

249 We predicted the candidate target genes of miR-206 by using online algorithms  
250 (DIANA-microT, miRanda, miRWalk, PicTar and TargetScan). CD39, the ectoenzyme catalyzing  
251 the degradation of extracellular ATP and ADP, is one of the candidate targets. The 3'-untranslated  
252 region (UTR) of CD39 contains nucleotides matching the seed sequence of hsa-miR-206 (Figure  
253 2A). Transfection of miR-206 mimic decreased the luciferase activity when co-transfected with  
254 the vector harboring wild-type CD39 3'-UTR, but had no effect on the luciferase activity when  
255 co-transfected with the vector containing mutant 3'-UTR or empty vector (Figure 2B). This  
256 indicates that miR-206 may directly act on the 3'-UTR of CD39 mRNA. Further, inhibition of  
257 miR-206 expression enhanced CD39 mRNA and protein expression, whereas overexpression of  
258 miR-206 suppressed CD39 expression (Figure 2C-E). These data indicate that CD39 is a target  
259 gene of miR-206.

260 In human asthma, we found that CD39 transcript levels were significantly increased in  
261 bronchial brushings from type 2-low and -high asthma patients compared to controls. Moreover,  
262 epithelial CD39 expression was lower in type 2-high asthma relative to type 2-low asthma (Figure  
263 2F). In support of CD39 as a target of miR-206, epithelial CD39 transcript levels negatively  
264 correlated with epithelial miR-206 expression (Figure 2G) in asthma patients.

265 **Extracellular ATP accumulation induces miR-206 downregulation and CD39 upregulation in**  
266 **human bronchial epithelial cells**

267 It was reported that BALF ATP concentration was increased in asthma patients after allergen

268 provocation [28]. In BALF from our symptomatic and treatment-naïve asthma patients, we  
269 measured ATP using luciferase bioluminescence. BALF ATP levels were markedly increased in  
270 both type 2-low and -high asthmatics compared to controls (Figure 3A). Moreover, BALF ATP  
271 levels were higher in type 2-high asthma relative to type 2-low asthma. This suggests that  
272 extracellular ATP is accumulated in the airways of symptomatic asthma patients.

273 Extracellular ATP accumulation upregulates CD39 expression in airway epithelial cells, which  
274 catalyzes the degradation of excessive extracellular ATP to maintain the homeostasis of  
275 microenvironment [53]. To determine whether miR-206-CD39 axis responds to extracellular ATP  
276 accumulation, we performed air-liquid interface culture of human bronchial epithelial (HBE) cells  
277 from healthy donors. House dust mite (HDM), the most clinically relevant allergen, rapidly  
278 increased ATP concentration in culture medium within 2 min. The ATP concentration peaked at  
279 1-2 h, and declined to baseline by 6h (Figure 3B). HDM exposure decreased miR-206 expression  
280 from 2 h to 12 h, with a maximum inhibition at 6 h (Figure 3C), and increased CD39 mRNA from  
281 2 h to 12 h, peaking at 6 h (Figure 3D). Furthermore, elimination of extracellular ATP by  
282 pretreatment with apyrase suppressed HDM-induced miR-206 downregulation and CD39  
283 upregulation at 6 h in HBE cells (Figure 3E and G). Exogenous ATP analog, ATP $\gamma$ S, directly  
284 decreased miR-206 expression and increased CD39 expression, and intensified HDM-induced  
285 miR-206 downregulation and CD39 upregulation (Figure 3F and H). Together, our data suggest  
286 that allergen-induced acute accumulation of extracellular ATP downregulates miR-206 and  
287 upregulates CD39 expression in airway epithelial cells. This may represent a protective  
288 mechanism to eliminate excessive extracellular ATP.

289 **Higher ATP levels associate with elevated IL-25 and TSLP expression in type 2-high asthma**

290 Allergen stimulates the release of ATP as an alarmin from airway epithelial cells to induce the  
291 expression of IL-33 [34]. We next examined the airway IL-25, IL-33 and TSLP expression in  
292 bronchial epithelial brushings and BALF using quantitative PCR and ELISA, respectively.  
293 Epithelial *IL25* transcript levels and BALF IL-25 protein levels were significantly higher in type  
294 2-high asthma when compared with type 2-low asthma and controls (Figure 4A, 4D). There were  
295 multiple splice variants of *IL-33* transcript, and the protein encoded by the *IL33* transcript without  
296 exons 3 and 4 is secreted as active cytokine [47]. We examined the expression of *IL33* transcript  
297 without exons 3 and 4 in bronchial epithelial brushings using RNase H-dependent quantitative  
298 PCR as previously reported [47]. However, there were no significant difference in this *IL33*  
299 transcript among the two asthma subsets and controls. Neither did we detect significant difference  
300 in IL-33 protein levels in BALF (Figure 4B, 4E). TSLP has short and long isoforms, and the long  
301 isoform is induced during inflammation [54]. We found that the long *TSLP* transcripts and BALF  
302 TSLP protein levels were higher in type 2-high asthma compared to type 2-low asthma and control  
303 subjects (Figure 4C, 4F). Our data suggest that airway expression of IL-25, TSLP whereas not  
304 IL-33 is elevated in type 2-high asthma.

305 Importantly, BALF ATP levels were strongly correlated with BALF IL-25 and TSLP protein  
306 levels (Figure 4G-H). This indicates that the more prominent accumulation of airway ATP may be  
307 responsible for elevated IL-25 and TSLP expression in type 2-high asthma.

308 **Extracellular ATP is essential for allergen-induced IL-25 and TSLP expression in human**  
309 **bronchial epithelial cells.**

310 We next examined the role of extracellular ATP in HDM-induced IL-25, IL-33 and TSLP  
311 expression in HBE cells cultured on an air-liquid interface. We found that HDM stimulation

312 increased *IL-25* mRNA expression in HBE cells and IL-25 protein levels in basal-lateral medium,  
313 peaking at 2 h and 6 h, respectively (Figure 5A and D). HDM also increased TSLP (the long  
314 transcript variant) mRNA and protein expression, peaking at 1 h and 6 h, respectively (Figure 5C  
315 and F). However, HDM stimulation did not alter the expression of IL-33 (the transcript without  
316 exons 3, 4) mRNA or protein (Figure 5B and E). Elimination of extracellular ATP by CD39  
317 overexpression or by using apyrase suppressed HDM-induced IL-25 and TSLP protein expression  
318 at 6 h (Figure 5G-J). In contrast, enhancing extracellular ATP by CD39 knockdown or by adding  
319 ATP $\gamma$ S further increased HDM-induced IL-25 and TSLP protein expression (Figure 5K-N). These  
320 data suggest that HDM-induced acute accumulation of extracellular ATP is required for IL-25 and  
321 TSLP upregulation in airway epithelial cells.

322 **MiR-206 regulates allergen-induced IL-25 and TSLP expression in bronchial epithelial cells**  
323 **via targeting CD39-extracellular ATP axis**

324 We next examined whether miR-206 regulates IL-25 and TSLP expression via targeting  
325 CD39-extracellular ATP axis in HDM-stimulated HBE cells. Inhibition of miR-206 expression by  
326 transfection with miR-206 inhibitor increased baseline and HDM-induced CD39 expression.  
327 Importantly, inhibition of miR-206 expression decreased the ATP concentration, and suppressed  
328 HDM-induced IL-25 and TSLP protein expression in the medium (Figure 6A-D). In contrast,  
329 miR-206 overexpression by transfection with miR-206 mimic suppressed baseline and  
330 HDM-induced CD39 expression, enhanced extracellular ATP, and further enhanced HDM-induced  
331 IL-25 and TSLP protein expression (Figure 6E-H). Our data indicates that miR-206 regulates  
332 epithelial IL-25 and TSLP expression by targeting CD39-extracellular ATP axis.

333 **Airway epithelial miR-206 regulates CD39 expression, BALF ATP concentration in a murine**

334 **model of allergic airway disease**

335 We investigated the role of epithelial miR-206 in a murine model of allergic airway  
336 inflammation of C57BL/6 mice sensitized and challenged with HDM. Using quantitative PCR, in  
337 situ hybridization, immunohistochemistry and luciferase bioluminescence, we found that HDM  
338 challenge decreased epithelial miR-206 expression, increased CD39 expression, and markedly  
339 enhanced BALF ATP levels compared to control mice. Inhibition of airway miR-206 expression  
340 by intranasal administration of miR-206 antagomir further enhanced HDM-induced CD39  
341 expression whereas suppressed HDM-induced BALF ATP accumulation (Figure 7A-D). In  
342 contrast, airway overexpression of miR-206 by intranasal administration of miR-206 agomir  
343 significantly suppressed HDM-induced CD39 expression, and further enhanced HDM-induced  
344 increase of ATP concentrations (Figure 7E-I). These data suggest that epithelial miR-206 targets  
345 CD39-extracellular ATP axis in the airway of a murine model of allergic airway disease.

346 **Airway miR-206 antagonism suppresses HDM-induced AHR, airway eosinophilia, mucus**  
347 **overproduction and type 2 cytokines expression in mice**

348 In the murine model of allergic airway disease, HDM sensitization and challenge increased  
349 airway resistance to methacholine, induced the infiltration of inflammatory cells around airways,  
350 increased airway mucus-producing cells and plasma IgE levels. Inhibition of airway miR-206  
351 expression by transfection with miR-206 antagomir significantly suppressed HDM-induced AHR,  
352 airway eosinophilic inflammation and mucus overproduction (Figure 8A-F). In contrast, airway  
353 miR-206 overexpression by transfection with miR-206 agomir further enhanced HDM-induced  
354 AHR, airway eosinophilia and mucus overproduction (Supplementary Figure A-F). Moreover,  
355 airway miR-206 antagonism suppressed HDM-induced expression of type 2 cytokines including

356 Il-4, Il-5 and Il-13, and decreased plasma IgE levels (Figure 8G-J), whereas miR-206  
357 overexpression further enhanced HDM-induced expression of type 2 cytokines in mice lungs and  
358 plasma IgE levels (Supplementary Figure G-J). Our data indicates that epithelial miR-206 play an  
359 essential role in allergic airway disease by regulating type 2 immune response.

360 **Airway miR-206 antagonism suppresses Il-25, Il-33, Tslp expression and ILC2s expansion in**  
361 **mice**

362 Since ILC2s play a pivotal role in type 2 response upon activation by IL-25 IL-33 and TSLP, we  
363 further examined the effect of airway miR-206 manipulation on Il-25, Il-33, Tslp expression and  
364 ILC2s expansion in mice. HDM sensitization and challenge increased Il-25, Il-33 and Tslp protein  
365 levels in BALF (Figure 9A-F). Meanwhile, HDM sensitization and challenge significantly  
366 increased the number of ILC2s (Lin<sup>-</sup>CD25<sup>+</sup>CD127<sup>+</sup>ST2<sup>+</sup>Sca-1<sup>+</sup>, gating strategy in Figure 9G) in  
367 single-cell suspension of lungs by flow cytometric analysis (Figure 9H-K). Airway miR-206  
368 antagonism suppressed HDM-induced Il-25, Il-33, and Tslp expression (Figure 9A-C) and ILC2s  
369 expansion (Figure 9H and J), whereas miR-206 overexpression further enhanced HDM-induced  
370 Il-25, Il-33 and Tslp expression (Figure 9D-F) and ILC2s expansion in mice lungs (Figure 9I and  
371 K). This suggests that epithelial miR-206 regulates HDM-induced Il-25, Il-33 and Tslp expression  
372 and ILC2s expansion in mouse models.

373

374 **DISCUSSION**

375 In the present study, we reported that epithelial miR-206 was differentially expressed between  
376 type 2-low and -high asthma patients who were symptomatic and treatment-naïve. Type 2-high  
377 asthma patients had higher miR-206 expression, lower epithelial CD39 expression, elevated  
378 BALF ATP levels, and higher epithelial IL-25, TSLP expression as compared with type 2-low  
379 asthma. Of note, BALF ATP levels strongly correlated with airway IL-25 and TSLP expression in  
380 asthma patients. The associations between these measurements were functionally validated in  
381 primary culture of HBE cells, and in a murine model of allergic airway inflammation.

382 MiRNAs play essential roles in the pathogenesis of asthma [39, 40, 55, 56]. So far, the  
383 differentially expressed epithelial miRNAs between type 2-low and high asthma remains unknown.  
384 We identified miR-206 as the most highly miRNA in type 2-high asthma relative to type 2-low  
385 asthma. However, compared to control subjects, miR-206 expression was downregulated in both  
386 asthma subsets. MiR-206 expression was also decreased in cultured HBE cells exposed to HDM  
387 and in the airways of mouse sensitized and challenged with HDM. Our findings are consistent  
388 with the report that miR-206 expression was decreased in airway wall of a mouse model of  
389 childhood allergic asthma [57]. Recent studies showed that miR-206 expression was also  
390 decreased in mouse models of occupational asthma [58, 59]. In human, it was reported that  
391 circulating miR-206 was useful to predict childhood asthma exacerbation [60], and plasma  
392 miR-206 expression differed between asthmatics with higher and lower blood eosinophil counts  
393 [61]. However, the mechanism underlying the less reduction of epithelial miR-206 in type 2-high  
394 asthma relative to type 2-low asthma requires further investigation.

395 To explore the role of miR-206 in asthma, we verified that CD39, an ecto-nucleotidase

396 degrading ATP, was a target of miR-206. So far, there is no studies addressing the regulation of  
397 airway CD39 in human asthma. Previous reports regarding the role of CD39 in animal asthma  
398 models were conflicting [32, 33]. We demonstrated that CD39 expression was increased in airway  
399 epithelium in human asthma and in mice sensitized and challenged with HDM. Consistent with  
400 higher expression of miR-206 in type 2-high asthma, CD39 expression was lower in type 2-high  
401 asthma relative to type 2-low asthma.

402 Extracellular ATP serves as a danger signal to alert the immune system of tissue damage. In our  
403 cohort of symptomatic and treatment-naïve asthma patients, BALF ATP concentrations were  
404 significantly increased, especially in type 2-high asthma patients. This is consistent with a  
405 previous report that allergen provocation enhanced airway BALF ATP accumulation in asthma  
406 patients [28]. The elevated airway ATP levels in our asthma patients might be due to exposure to  
407 environmental aeroallergen including HDM and/or airway virus infections, the main triggers of  
408 asthma exacerbation [12, 62]. It was reported that rhinovirus infection stimulated bronchial  
409 smooth muscle cells to release ATP [63], and influenza A virus infection increased BALF ATP  
410 levels in mice [64].

411 In our *in vitro* system, we demonstrated that HDM-induced acute extracellular ATP  
412 accumulation was responsible for miR-206 downregulation and CD39 upregulation in HBE cells  
413 on an air-liquid interface. Since CD39 catalyzes ATP degradation, the CD39 upregulation in  
414 asthma patients and in HDM-exposed HBE cells may represent an inhibitory feedback response to  
415 excessive ATP, by which striving to maintain airway homeostasis.

416 In human asthma, we previously reported that epithelial *IL-25* mRNA expression was  
417 upregulated in a subset of asthma patients featured by type 2 inflammation [42]. Here, in a

418 different cohort of asthmatics, we reported that airway expression of IL-25 and TSLP whereas not  
419 IL-33 was elevated in type 2-high asthma using ELISA and qPCR. The Taqman qPCR primers and  
420 probes were previously reported for the *IL-33* isoform without exons 3 and 4, and the long isoform  
421 of *TSLP*, and these isoforms were associated with type 2 inflammation [47, 54]. So far, there have  
422 been few head-to-head studies of IL-25, IL-33 and TSLP expression in human asthma. Various  
423 expression patterns of these cytokines were reported in different populations. In Korean, plasma  
424 IL-25 whereas not IL-33 or TSLP was increased in patients with aspirin-exacerbated respiratory  
425 disease characterized by asthma, nasal polyps and chronic eosinophilic sinusitis [21]. Elevated  
426 IL-25, but not IL-33 or TSLP mRNA, was reported in sputum cells from uncontrolled asthmatics  
427 in Belgium [22]. In contrast, increased expression of IL-33 and TSLP whereas not IL-25 was  
428 reported in asthma patients in London [23], Poland [24], and New York [25]. This suggests that  
429 ethnicity and region should be considered in studies on these cytokines. Recently, a new concept  
430 “regiotype” was introduced for allergic diseases, referring to regional difference between  
431 endotypes due to different allergens and other environmental influences [2]. In chronic  
432 rhinosinusitis with nasal polyps (CRSwNP), a disease related to asthma, various expression  
433 patterns of IL-25, IL-33 and TSLP in different population and regions have been described.  
434 Reports of IL-25 upregulation in CRSwNP came from Asian countries including Korea [65],  
435 Japan [66] and China [67], whereas negative results of IL-25 were from USA [68], Australia [69]  
436 and Turkey [70]. Our data of airway IL-25, IL-33 and TSLP expression in asthma patients will  
437 provide evidence for the novel therapies targeting these cytokines in China.

438 The upstream signaling pathway regulating the expression of epithelial IL-25 and TSLP remains  
439 largely unknown. Here we reported that BALF ATP concentrations strongly correlated with airway

440 IL-25 and TSLP expression. *In vitro*, allergen-induced acute accumulation of extracellular ATP  
441 was required and sufficient for IL-25 and TSLP expression. Further, epithelial miR-206 regulated  
442 IL-25 and TSLP expression by targeting CD39-extracellular ATP axis both *in vitro* and *in vivo*.  
443 HDM sensitization and challenge decreased airway miR-206 expression while increased Cd39  
444 expression, BALF ATP concentration, Il-25, Il-33, Tslp expression, and ILC2s expansion in mice.  
445 Airway miR-206 antagonism before HDM challenge suppressed Il-25, Il-33, Tslp expression,  
446 ILC2s expansion, type 2 cytokine expression, and the cardinal features of asthma in mice. On the  
447 other hand, miR-206 overexpression had opposite effects.

448 As summarized in Figure 10, our findings suggest that epithelial miR-206 is downregulated in  
449 both asthma subsets. Compared with type 2-low asthma, less reduction of epithelial miR-206  
450 resulted in higher miR-206, lower CD39 expression and impaired capacity to eliminate  
451 extracellular ATP in type 2-high asthma. Consequently, more extracellular ATP is accumulated  
452 leading to higher expression of IL-25, TSLP and more prominent type 2 inflammation in type  
453 2-high asthma. Alternative cascades may also explain the effect of miR-206 perturbation on type 2  
454 response in mice. For example, increased extracellular ATP can directly activate other immune  
455 cells including dendritic cells [28]. ATP can also promote dendritic cell-driven Th2 sensitization  
456 by inducing epithelial cells to release inflammatory cytokines [71, 72].

457 In conclusion, epithelial miR-206 regulates airway IL-25 and TSLP expression and type 2  
458 inflammation in asthma via targeting CD39-extracellular ATP axis. This pathway contributes, at  
459 least in part, to the development of human type 2-high asthma and represents a novel therapeutic  
460 target for this endotype.

461

462

463 **Conflicts of interests:** The authors have declared that no conflict of interest exists.

464

465 **Funding:** This work was supported by National Natural Science Foundation of China (grant  
466 91742108, 81670019, 81800026, 81600023), National Key Research and Development Program  
467 of China (2016YFC1304400), and Hubei Province Natural Science Foundation (grant  
468 2017CFA016).

469

470 **Acknowledgements:** The authors thank all participants in this study; Xiaoling Rao and Mei Liu  
471 for bronchoscopy support; Wang Ni, Shixin Chen and Kun Zhang for spirometry measurement.

472

473 **Author contributions:** G.Z. designed the research, conceived of the manuscript and had primary  
474 responsibility for writing. K.Z., Y.F., Y.L., W.W., C.C., D.C., S.C., J.G., and G.C. performed  
475 experiments. K.Z., Y.F., Y.L., L.Y., D.C., and G.Z. analyzed data. K.Z., Y.F., Y.L., L.Y., D.C., and  
476 G.Z. interpreted results of experiments. K.Z., Y.F., and G.Z. prepared figures and drafted  
477 manuscript. G.Z. edited and revised manuscript. All authors reviewed and approved the  
478 manuscript.

479

480

## 481 REFERENCES

- 482 1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012; 18(5):  
483 716-725.
- 484 2. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of  
485 allergic diseases. *J Clin Invest* 2019; 129(4): 1493-1503.
- 486 3. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type  
487 2-driven inflammation defines major subphenotypes of asthma. *American journal of respiratory and critical care*  
488 *medicine* 2009; 180(5): 388-395.
- 489 4. Peebles RS, Jr., Aronica MA. Proinflammatory Pathways in the Pathogenesis of Asthma. *Clin Chest Med* 2019;  
490 40(1): 29-50.
- 491 5. Hammad H, Lambrecht BN. Barrier Epithelial Cells and the Control of Type 2 Immunity. *Immunity* 2015; 43(1):  
492 29-40.
- 493 6. Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell-derived cytokines: more than just signaling the alarm. *J Clin*  
494 *Invest* 2019; 129(4): 1441-1451.
- 495 7. Hiemstra PS, McCray PB, Jr., Bals R. The innate immune function of airway epithelial cells in inflammatory lung  
496 disease. *Eur Respir J* 2015; 45(4): 1150-1162.
- 497 8. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD,  
498 Zurawski G, Leach MW, Gorman DM, Rennick DM. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies  
499 in vivo. *Immunity* 2001; 15(6): 985-995.
- 500 9. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman  
501 DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2  
502 and induces T helper type 2-associated cytokines. *Immunity* 2005; 23(5): 479-490.
- 503 10. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K,  
504 Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal-Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ.  
505 Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol* 2002;  
506 3(7): 673-680.
- 507 11. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation  
508 in an asthma model. *J Exp Med* 2005; 202(6): 829-839.
- 509 12. Bloodworth MH, Rusznak M, Pfister CC, Zhang J, Bastarache L, Calvillo SA, Chappell JD, Boyd KL, Toki S,  
510 Newcomb DC, Stier MT, Zhou W, Goleniewska K, Moore ML, Hartert TV, Niswender KD, Peebles RS, Jr. Glucagon-like  
511 peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology.  
512 *The Journal of allergy and clinical immunology* 2018; 142(2): 683-687 e612.
- 513 13. Vercelli D. When Innate Responses Matter: ILC2s Loom Large in Allergic Airway Inflammation. *American journal*  
514 *of respiratory and critical care medicine* 2017; 195(12): 1544-1546.
- 515 14. Causton B, Pardo-Saganta A, Gillis J, Discipio K, Kooistra T, Rajagopal J, Xavier RJ, Cho JL, Medoff BD. CARMA3  
516 Mediates Allergic Lung Inflammation in Response to *Alternaria alternata*. *Am J Respir Cell Mol Biol* 2018; 59(6):  
517 684-694.
- 518 15. Altman MC, Lai Y, Nolin JD, Long S, Chen CC, Piliponsky AM, Altemeier WA, Larmore M, Frevert CW, Mulligan MS,  
519 Ziegler SF, Debley JS, Peters MC, Hallstrand TS. Airway epithelium-shifted mast cell infiltration regulates asthmatic  
520 inflammation via IL-33 signaling. *J Clin Invest* 2019; 129(11): 4979-4991.
- 521 16. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, Hippe A, Corrigan CJ, Dong C, Homey B, Yao Z,  
522 Ying S, Huston DP, Liu YJ. IL-25 augments type 2 immune responses by enhancing the expansion and functions of  
523 TSLP-DC-activated Th2 memory cells. *J Exp Med* 2007; 204(8): 1837-1847.

- 524 17. Endo Y, Hirahara K, Iinuma T, Shinoda K, Tumes DJ, Asou HK, Matsugae N, Obata-Ninomiya K, Yamamoto H,  
525 Motohashi S, Oboki K, Nakae S, Saito H, Okamoto Y, Nakayama T. The interleukin-33-p38 kinase axis confers memory  
526 T helper 2 cell pathogenicity in the airway. *Immunity* 2015; 42(2): 294-308.
- 527 18. Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN. Blocking  
528 IL-25 prevents airway hyperresponsiveness in allergic asthma. *The Journal of allergy and clinical immunology* 2007;  
529 120(6): 1324-1331.
- 530 19. Suzukawa M, Morita H, Nambu A, Arae K, Shimura E, Shibui A, Yamaguchi S, Suzukawa K, Nakanishi W, Oboki K,  
531 Kajiwara N, Ohno T, Ishii A, Korner H, Cua DJ, Suto H, Yoshimoto T, Iwakura Y, Yamasoba T, Ohta K, Sudo K, Saito H,  
532 Okumura K, Broide DH, Matsumoto K, Nakae S. Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F,  
533 is crucial for murine asthma. *J Immunol* 2012; 189(7): 3641-3652.
- 534 20. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. *Nat Rev*  
535 *Immunol* 2010; 10(2): 103-110.
- 536 21. Lee JU, Chang HS, Lee HJ, Bae DJ, Son JH, Park JS, Choi JS, Hwang HG, Park CS. Association of interleukin-25  
537 levels with development of aspirin induced respiratory diseases. *Respir Med* 2017; 123: 71-78.
- 538 22. Seys SF, Grabowski M, Adriaensen W, Decraene A, Dilissen E, Vanoirbeek JA, Dupont LJ, Ceuppens JL, Bullens  
539 DM. Sputum cytokine mapping reveals an 'IL-5, IL-17A, IL-25-high' pattern associated with poorly controlled asthma.  
540 *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2013; 43(9):  
541 1009-1017.
- 542 23. Li Y, Wang W, Lv Z, Chen Y, Huang K, Corrigan CJ, Ying S. Elevated Expression of IL-33 and TSLP in the Airways of  
543 Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. *J Immunol* 2018; 200(7): 2253-2262.
- 544 24. Gluck J, Rymarczyk B, Kasprzak M, Rogala B. Increased Levels of Interleukin-33 and Thymic Stromal  
545 Lymphopoietin in Exhaled Breath Condensate in Chronic Bronchial Asthma. *Int Arch Allergy Immunol* 2016; 169(1):  
546 51-56.
- 547 25. Bleck B, Kazeros A, Bakal K, Garcia-Medina L, Adams A, Liu M, Lee RA, Tse DB, Chiu A, Grunig G, Egan JP, 3rd,  
548 Reibman J. Coexpression of type 2 immune targets in sputum-derived epithelial and dendritic cells from asthmatic  
549 subjects. *The Journal of allergy and clinical immunology* 2015; 136(3): 619-627 e615.
- 550 26. O'Grady SM, Patil N, Melkamu T, Maniak PJ, Lancto C, Kita H. ATP release and Ca<sup>2+</sup> signalling by human  
551 bronchial epithelial cells following *Alternaria* aeroallergen exposure. *J Physiol* 2013; 591(18): 4595-4609.
- 552 27. Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, Rogers N, Osorio F, Reis e Sousa C,  
553 Hammad H, Lambrecht BN. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled  
554 antigens and inflammatory mediator of allergic asthma. *Immunity* 2011; 34(4): 527-540.
- 555 28. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D,  
556 Di Virgilio F, Virchow JC, Jr., Lambrecht BN. Extracellular ATP triggers and maintains asthmatic airway inflammation by  
557 activating dendritic cells. *Nat Med* 2007; 13(8): 913-919.
- 558 29. Picher M, Burch LH, Hirsh AJ, Szychala J, Boucher RC. Ecto 5'-nucleotidase and nonspecific alkaline phosphatase.  
559 Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. *J Biol Chem* 2003; 278(15): 13468-13479.
- 560 30. Leal DB, Streher CA, Neu TN, Bittencourt FP, Leal CA, da Silva JE, Morsch VM, Schetinger MR. Characterization of  
561 NTPDase (NTPDase1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes.  
562 *Biochim Biophys Acta* 2005; 1721(1-3): 9-15.
- 563 31. Chavez J, Vargas MH, Rebollar-Ayala DC, Diaz-Hernandez V, Cruz-Valderrama JE, Flores-Soto E, Flores-Garcia M,  
564 Jimenez-Vargas NN, Barajas-Lopez C, Montano LM. Inhibition of extracellular nucleotides hydrolysis intensifies the  
565 allergic bronchospasm. A novel protective role of ectonucleotidases. *Allergy* 2013; 68(4): 462-471.
- 566 32. Li P, Gao Y, Cao J, Wang W, Chen Y, Zhang G, Robson SC, Wu Y, Yang J. CD39+ regulatory T cells attenuate allergic  
567 airway inflammation. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical*

- 568 *Immunology* 2015; 45(6): 1126-1137.
- 569 33. Idzko M, C KA, Muller T, Durk T, Grimm M, Baudiss K, Vieira RP, Cicko S, Boehlke C, Zech A, Sorichter S, Pelletier J,  
570 Sevigny J, Robson SC. Attenuated allergic airway inflammation in Cd39 null mice. *Allergy* 2013; 68(4): 472-480.
- 571 34. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an  
572 airborne allergen and triggers IL-33 release and innate Th2-type responses. *J Immunol* 2011; 186(7): 4375-4387.
- 573 35. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. *Nat Rev*  
574 *Immunol* 2013; 13(9): 666-678.
- 575 36. Solberg OD, Ostrin EJ, Love MI, Peng JC, Bhakta NR, Hou L, Nguyen C, Solon M, Barczak AJ, Zlock LT, Blagev DP,  
576 Finkbeiner WE, Ansel KM, Arron JR, Erle DJ, Woodruff PG. Airway epithelial miRNA expression is altered in asthma.  
577 *American journal of respiratory and critical care medicine* 2012; 186(10): 965-974.
- 578 37. Singh PB, Pua HH, Happ HC, Schneider C, von Moltke J, Locksley RM, Baumjohann D, Ansel KM. MicroRNA  
579 regulation of type 2 innate lymphoid cell homeostasis and function in allergic inflammation. *J Exp Med* 2017; 214(12):  
580 3627-3643.
- 581 38. Simpson LJ, Patel S, Bhakta NR, Choy DF, Brightbill HD, Ren X, Wang Y, Pua HH, Baumjohann D, Montoya MM,  
582 Panduro M, Remedios KA, Huang X, Fahy JV, Arron JR, Woodruff PG, Ansel KM. A microRNA upregulated in asthma  
583 airway T cells promotes TH2 cytokine production. *Nat Immunol* 2014; 15(12): 1162-1170.
- 584 39. Polikepahad S, Knight JM, Naghavi AO, Oplt T, Creighton CJ, Shaw C, Benham AL, Kim J, Soibam B, Harris RA,  
585 Coarfa C, Zariif A, Milosavljevic A, Batts LM, Kheradmand F, Gunaratne PH, Corry DB. Proinflammatory role for let-7  
586 microRNAs in experimental asthma. *J Biol Chem* 2010; 285(39): 30139-30149.
- 587 40. Kumar M, Ahmad T, Sharma A, Mabalirajan U, Kulshreshtha A, Agrawal A, Ghosh B. Let-7 microRNA-mediated  
588 regulation of IL-13 and allergic airway inflammation. *The Journal of allergy and clinical immunology* 2011; 128(5):  
589 1077-1085 e1071-1010.
- 590 41. Huo X, Zhang K, Yi L, Mo Y, Liang Y, Zhao J, Zhang Z, Xu Y, Zhen G. Decreased epithelial and plasma miR-181b-5p  
591 expression associates with airway eosinophilic inflammation in asthma. *Clinical and experimental allergy : journal of*  
592 *the British Society for Allergy and Clinical Immunology* 2016; 46(10): 1281-1290.
- 593 42. Cheng D, Xue Z, Yi L, Shi H, Zhang K, Huo X, Bonser LR, Zhao J, Xu Y, Erle DJ, Zhen G. Epithelial interleukin-25 is a  
594 key mediator in Th2-high, corticosteroid-responsive asthma. *American journal of respiratory and critical care*  
595 *medicine* 2014; 190(6): 639-648.
- 596 43. Kelsen SG, Mardini IA, Zhou S, Benovic JL, Higgins NC. A technique to harvest viable tracheobronchial epithelial  
597 cells from living human donors. *Am J Respir Cell Mol Biol* 1992; 7(1): 66-72.
- 598 44. Zhen G, Park SW, Nguyenvu LT, Rodriguez MW, Barbeau R, Paquet AC, Erle DJ. IL-13 and epidermal growth factor  
599 receptor have critical but distinct roles in epithelial cell mucin production. *Am J Respir Cell Mol Biol* 2007; 36(2):  
600 244-253.
- 601 45. Yi L, Cheng D, Zhang K, Huo X, Mo Y, Shi H, Di H, Zou Y, Zhang H, Zhao J, Xu Y, Erle DJ, Zhen G. Intelectin  
602 contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic  
603 dermatitis. *Mucosal Immunol* 2017; 10(6): 1491-1503.
- 604 46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  
605 2(-Delta Delta C(T)) Method. *Methods* 2001; 25(4): 402-408.
- 606 47. Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, Wesolowska-Andersen A,  
607 Gonzalez JR, MacLeod HJ, Christian LS, Yuan S, Barry L, Woodruff PG, Ansel KM, Nocka K, Seibold MA, Fahy JV.  
608 Alternative splicing of interleukin-33 and type 2 inflammation in asthma. *Proceedings of the National Academy of*  
609 *Sciences of the United States of America* 2016; 113(31): 8765-8770.
- 610 48. Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, Woodruff PG. A qPCR-based metric of Th2  
611 airway inflammation in asthma. *Clinical and translational allergy* 2013; 3(1): 24.

- 612 49. Tasena H, Boudewijn IM, Faiz A, Timens W, Hylkema MN, Berg M, Ten Hacken NHT, Brandsma CA, Heijink IH, van  
613 den Berge M. MiR-31-5p: A shared regulator of chronic mucus hypersecretion in asthma and chronic obstructive  
614 pulmonary disease. *Allergy* 2020; 75(3): 703-706.
- 615 50. Comer BS, Camoretti-Mercado B, Kogut PC, Halayko AJ, Solway J, Gerthoffer WT. MicroRNA-146a and  
616 microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. *American journal of  
617 physiology Lung cellular and molecular physiology* 2014; 307(9): L727-734.
- 618 51. Perry MM, Baker JE, Gibeon DS, Adcock IM, Chung KF. Airway smooth muscle hyperproliferation is regulated by  
619 microRNA-221 in severe asthma. *Am J Respir Cell Mol Biol* 2014; 50(1): 7-17.
- 620 52. Zhang K, Liang Y, Feng Y, Wu W, Zhang H, He J, Hu Q, Zhao J, Xu Y, Liu Z, Zhen G. Decreased epithelial and sputum  
621 miR-221-3p associates with airway eosinophilic inflammation and CXCL17 expression in asthma. *American journal of  
622 physiology Lung cellular and molecular physiology* 2018; 315(2): L253-L264.
- 623 53. Burch LH, Picher M. E-NTPDases in human airways: Regulation and relevance for chronic lung diseases.  
624 *Purinergic signalling* 2006; 2(2): 399-408.
- 625 54. Fornasa G, Tsilingiri K, Caprioli F, Botti F, Mapelli M, Meller S, Kislat A, Homey B, Di Sabatino A, Sonzogni A, Viale  
626 G, Diaferia G, Gori A, Longhi R, Penna G, Rescigno M. Dichotomy of short and long thymic stromal lymphopoietin  
627 isoforms in inflammatory disorders of the bowel and skin. *The Journal of allergy and clinical immunology* 2015;  
628 136(2): 413-422.
- 629 55. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates  
630 IL-12p35 expression. *J Immunol* 2009; 182(8): 4994-5002.
- 631 56. Malmhall C, Alawieh S, Lu Y, Sjostrand M, Bossios A, Eldh M, Radinger M. MicroRNA-155 is essential for  
632 T(H)2-mediated allergen-induced eosinophilic inflammation in the lung. *The Journal of allergy and clinical  
633 immunology* 2014; 133(5): 1429-1438, 1438 e1421-1427.
- 634 57. Collison A, Siegle JS, Hansbro NG, Kwok CT, Herbert C, Mattes J, Hitchins M, Foster PS, Kumar RK. Epigenetic  
635 changes associated with disease progression in a mouse model of childhood allergic asthma. *Dis Model Mech* 2013;  
636 6(4): 993-1000.
- 637 58. Lin CC, Law BF, Siegel PD, Hettick JM. Circulating miRs-183-5p, -206-3p and -381-3p may serve as novel  
638 biomarkers for 4,4'-methylene diphenyl diisocyanate exposure. *Biomarkers* 2019; 24(1): 76-90.
- 639 59. Lin CC, Law BF, Hettick JM. Acute 4,4'-Methylene Diphenyl Diisocyanate Exposure-Mediated Downregulation of  
640 miR-206-3p and miR-381-3p Activates Inducible Nitric Oxide Synthase Transcription by Targeting Calcineurin/NFAT  
641 Signaling in Macrophages. *Toxicol Sci* 2020; 173(1): 100-113.
- 642 60. Kho AT, McGeachie MJ, Moore KG, Sylvia JM, Weiss ST, Tantisira KG. Circulating microRNAs and prediction of  
643 asthma exacerbation in childhood asthma. *Respir Res* 2018; 19(1): 128.
- 644 61. Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A, Ishmael FT. Circulating microRNAs as  
645 biomarkers in patients with allergic rhinitis and asthma. *The Journal of allergy and clinical immunology* 2016; 137(5):  
646 1423-1432.
- 647 62. Leung TF, To MY, Yeung AC, Wong YS, Wong GW, Chan PK. Multiplex molecular detection of respiratory  
648 pathogens in children with asthma exacerbation. *Chest* 2010; 137(2): 348-354.
- 649 63. Calven J, Akbarshahi H, Menzel M, Ayata CK, Idzko M, Bjermer L, Uller L. Rhinoviral stimuli, epithelial factors and  
650 ATP signalling contribute to bronchial smooth muscle production of IL-33. *J Transl Med* 2015; 13: 281.
- 651 64. Wolk KE, Lazarowski ER, Traylor ZP, Yu EN, Jewell NA, Durbin RK, Durbin JE, Davis IC. Influenza A virus inhibits  
652 alveolar fluid clearance in BALB/c mice. *American journal of respiratory and critical care medicine* 2008; 178(9):  
653 969-976.
- 654 65. Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, Kong IG, Mo JH, Yang MS, Jin HR, Park JW, Kim DW. IL-25 as a  
655 novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. *The Journal of allergy and clinical*

656 *immunology* 2015; 135(6): 1476-1485 e1477.

657 66. Iinuma T, Okamoto Y, Yamamoto H, Inamine-Sasaki A, Ohki Y, Sakurai T, Funakoshi U, Yonekura S, Sakurai D,  
658 Hirahara K, Nakayama T. Interleukin-25 and mucosal T cells in noneosinophilic and eosinophilic chronic rhinosinusitis.  
659 *Ann Allergy Asthma Immunol* 2015; 114(4): 289-298.

660 67. Chen F, Hong H, Sun Y, Hu X, Zhang J, Xu G, Zhao W, Li H, Shi J. Nasal interleukin 25 as a novel biomarker for  
661 patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness: A pilot study. *Ann Allergy*  
662 *Asthma Immunol* 2017; 119(4): 310-316 e312.

663 68. Ogasawara N, Klingler AI, Tan BK, Poposki JA, Hulse KE, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS,  
664 Conley DB, Kern RC, Schleimer RP, Kato A. Epithelial activators of type 2 inflammation: Elevation of thymic stromal  
665 lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois. *Allergy* 2018;  
666 73(11): 2251-2254.

667 69. Miljkovic D, Bassiouni A, Cooksley C, Ou J, Hauben E, Wormald PJ, Vreugde S. Association between group 2  
668 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. *Allergy* 2014; 69(9): 1154-1161.

669 70. Ozturan A, Eyigor H, Eyigor M, Osma U, Yilmaz MD, Selcuk OT, Renda L, Gultekin M. The role of IL-25 and IL-33 in  
670 chronic rhinosinusitis with or without nasal polyps. *Eur Arch Otorhinolaryngol* 2017; 274(1): 283-288.

671 71. Muller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC, Jr., Luttmann W,  
672 Norgauer J, Di Virgilio F, Idzko M. The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca<sup>2+</sup> and IL-8  
673 secretion. *Am J Respir Cell Mol Biol* 2005; 33(6): 601-609.

674 72. Douillet CD, Robinson WP, 3rd, Milano PM, Boucher RC, Rich PB. Nucleotides induce IL-6 release from human  
675 airway epithelia via P2Y2 and p38 MAPK-dependent pathways. *American journal of physiology Lung cellular and*  
676 *molecular physiology* 2006; 291(4): L734-746.

677

678

679

680 **FIGURE LEGENDS:**

681 **Figure 1. Epithelial miRNA expression profiling reveals differentially expressed miRNAs**  
682 **including miR-206 between type 2-low and -high asthma.** (A) Twenty differentially expressed  
683 epithelial miRNAs between subjects with type 2-low asthma (n = 4) and type 2-high asthma (n = 4)  
684 were identified using microarrays. Each column represents data from one subject. Colors represent  
685 fold change relative to the mean value of type 2-low asthma. (B) miR-206 transcript levels in  
686 bronchial brushings from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37)  
687 and healthy controls (n = 26) were determined by quantitative PCR. The transcript levels are  
688 expressed as relative to the median value of healthy controls and log<sub>2</sub> transformed. One-way  
689 ANOVA with Bonferroni's post hoc test was performed.

690 **Figure 2. The expression of CD39, a target of miR-206, is increased in airway epithelial cells**  
691 **in human asthma.** (A) The 3'-UTR of CD39 contains region that matches the seed sequence of  
692 hsa-miR-206. (B) 3'-UTR luciferase report assay with vector harboring wild-type (WT), mutant  
693 CD39 3'-UTR or no 3'-UTR (control) co-transfected with miR-206 mimic or non-targeting control.  
694 Luciferase activity was measured by dual-luciferase reporter assay system. The firefly luciferase  
695 activity was normalized to renilla luciferase activity. n = 4 per group. (C, D) CD39 transcript  
696 levels in BEAS-2B cells after transfection with miR-206 mimic (C) or inhibitor (D) were  
697 determined by quantitative PCR. The transcript levels are expressed as relative to the mean value  
698 of control group (two-tailed Student's *t* test). n = 4 per group. Data are mean ± SD. (E) CD39  
699 protein expression in BEAS-2B cells after transfection with miR-206 mimic and inhibitor were  
700 determined by Western blotting. (F) CD39 transcript levels in bronchial brushings from type 2-low  
701 asthma patients (n = 20), type 2-high asthma patients (n=37) and healthy controls (n = 26) were

702 determined by quantitative PCR. The transcript levels are expressed as relative to the median  
703 value of healthy controls and log<sub>2</sub> transformed (one-way ANOVA with Bonferroni's post hoc test).  
704 (G) Spearman's rank order correlation assay between epithelial CD39 and miR-206 transcript  
705 levels in all asthma patients (n = 57).

706 **Figure 3. Acute extracellular ATP accumulation is responsible for allergen-induced miR-206**

707 **downregulation and CD39 upregulation in bronchial epithelial cells.** (A) ATP levels in BALF

708 from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37), and healthy

709 controls (n = 26) were determined by luciferase bioluminescence. BALF ATP levels were

710 expressed as luminometer counts (one-way ANOVA with Bonferroni's post hoc test). (B) ATP

711 concentration in culture medium collected at indicated time points after HDM stimulation was

712 measured by luciferase bioluminescence. (C, D) Transcript levels of miR-206 (C) and CD39 (D)

713 in HBE cells harvested at indicated time points after HDM stimulation were determined by

714 quantitative PCR. n = 4-6 per time point combined from 2 experiments using HBE cells from 2

715 healthy donors. Data are mean ± SD. \**P*<0.05; \*\**P*<0.01; \*\*\**P*<0.001 (one-way ANOVA with

716 Bonferroni's post hoc test). (E-F) MiR-206 transcript levels in HBE cells pretreated with apyrase

717 or saline for 2 h before adding HDM and stimulation for 6 h (E), and treated with ATPγS or saline

718 with or without HDM for 6h (F). (G, H) CD39 transcript levels in HBE cells pretreated with

719 apyrase or saline for 2 h before adding HDM and stimulation for 6 h (G), and treated with ATPγS

720 or saline with or without HDM for 6h (H). The transcript levels are expressed as relative to the

721 mean value of control group and log<sub>2</sub> transformed. n = 4-6 wells per group combined from 2

722 experiments using HBE cells from 2 healthy donors. Data are mean ± SD. \**P*<0.05; \*\**P*<0.01;

723 \*\*\**P*<0.001 (one-way ANOVA with Bonferroni's post hoc test).

724 **Figure 4. Airway IL-25 and TSLP expression is elevated in type 2-high asthma, and**  
725 **correlates with BALF ATP levels in asthma.** (A-C) The transcripts of *IL-25* (A), *IL-33* without  
726 exons 3, 4 (B), and long isoform of *TSLP* (C) in bronchial epithelial brushings from type 2-low  
727 asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using  
728 quantitative PCR with Taqman primers and probes. For detection of *IL-33* transcript without exons  
729 3 and 4, RNase H-dependent quantitative PCR was performed. The transcript levels are expressed  
730 as relative to the median value of healthy controls and log2 transformed. (D-F) IL-25 (D), IL-33  
731 (E) and TSLP (F) protein levels in BALF from type 2-low asthma (n = 20), type 2-high asthma (n  
732 = 37) and healthy controls (n = 26) were determined using ELISA. One-way ANOVA with  
733 Bonferroni's post hoc test was performed. (G-H) Spearman's rank order correlation assays between  
734 BALF ATP levels and BALF IL-25 protein levels (G), and TSLP protein levels (H).

735 **Figure 5. Extracellular ATP is required and sufficient for IL-25 and TSLP expression in**  
736 **bronchial epithelial cells.** (A-C) The transcripts of *IL-25* (A), *IL-33* without exons 3, 4 (B), and  
737 the long isoform of TSLP (C) in HBE cells harvested at indicated time points after HDM  
738 stimulation were determined by quantitative PCR. (D-F) IL-25 (D), IL-33 (E) and TSLP (F)  
739 protein levels in culture medium collected at indicated time points after HDM stimulation were  
740 determined by ELISA. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  (one-way ANOVA with Bonferroni's post  
741 hoc test). n = 5-6 wells per time points combined from 2 experiments using HBE cells from 2  
742 healthy donors. (G, H) IL-25 (G) and TSLP (H) protein levels in culture medium after transfection  
743 with empty or CD39 expression vector and stimulated with or without HDM for 6 h were  
744 determined by ELISA. (I, J) IL-25 (I) and TSLP (J) protein levels in culture medium after  
745 pretreatment with apyrase or saline and stimulated with or without HDM for 6 h were determined

746 by ELISA. (K, L) IL-25 (K) and TSLP (L) protein levels in culture medium after transfection with  
747 scrambled or CD39 siRNA and stimulated with or without HDM for 6 h were determined by  
748 ELISA. (M, N) IL-25 (M) and TSLP (N) protein levels in culture medium after treatment with  
749 ATP $\gamma$ S or saline and with or without HDM for 6h were determined by ELISA. n = 4 wells per  
750 group. Data are mean  $\pm$  SD. \* $P$ <0.05; \*\* $P$ <0.01; \*\*\* $P$ <0.001 (one-way ANOVA with  
751 Bonferroni's post hoc test). n = 4-6 wells per group combined from 2 experiments using HBE cells  
752 from 2 healthy donors.

753 **Figure 6. MiR-206 regulates allergen-induced IL-25 and TSLP expression via targeting**  
754 **CD39 - extracellular ATP axis in bronchial epithelial cells.** (A) CD39 transcript levels in HBE  
755 cells transfected with control or miR-206 inhibitor and stimulated with or without HDM for 6 h  
756 were determined by quantitative PCR. (B) ATP concentration in culture medium after transfection  
757 with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were measured by  
758 luciferase bioluminescence. (C, D) IL-25 (C), and TSLP (D) protein levels in culture medium after  
759 transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were  
760 determined by ELISA. (E) CD39 transcript levels in HBE cells transfected with control or  
761 miR-206 mimic and stimulated with or without HDM for 6 h were determined by quantitative  
762 PCR. (F) ATP concentration in culture medium after transfection with control or miR-206 mimic  
763 and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (G, H)  
764 IL-25 (G), and TSLP (H) protein levels in culture medium after transfection with control or  
765 miR-206 mimic and stimulation with or without HDM for 6 h were determined by ELISA. n = 4  
766 wells per group. Data are mean  $\pm$  SD. \* $P$ <0.05; \*\* $P$ <0.01; \*\*\* $P$ <0.001 (one-way ANOVA with  
767 Bonferroni's post hoc test). n = 5-6 wells per group combined from 2 experiments using HBE cells

768 from 2 healthy donors.

769 **Figure 7. Epithelial miR-206 targets CD39-extracellular ATP axis in a murine model of**  
770 **allergic airway inflammation.** (A) Experimental schedule as described in Methods. (B-D)  
771 MiR-206 (B) and CD39 (C) transcript levels in lungs, and ATP levels in BALF (D) were  
772 determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally  
773 administered with control or miR-206 antagomir and challenged with HDM or saline. (E-G)  
774 MiR-206 (E) and CD39 (F) transcript levels in lungs, and ATP levels in BALF (G) were  
775 determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally  
776 administered with control or miR-206 agomir and challenged with HDM or saline. The transcript  
777 level is expressed as relative to the mean value of control group and log<sub>2</sub> transformed. BALF ATP  
778 levels were expressed as luminometer counts. n = 6 - 10 mice per group combined from 2  
779 independent experiments. Data are mean ± SD. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001 (one-way  
780 ANOVA with Bonferroni's post hoc test). (H, I) Representative images of *in situ* hybridization of  
781 miR-206 (H), and immunohistochemistry of CD39 (I) in lung sections of mice intranasally  
782 administered with control or miR-206 agomir and challenged with HDM or saline. Scale bar = 50  
783 μm.

784 **Figure 8. Airway miR-206 antagonism suppresses HDM-induced AHR, airway inflammation,**  
785 **mucus overproduction and type 2 response in mice.** (A) Respiratory resistance in response to  
786 different concentration of intravenous acetylcholine at 24 h after the last HDM or saline challenge  
787 in mice intranasally administered with control or miR-206 antagomir. (B) Inflammatory scores of  
788 lung sections from mice intranasally administered with control or miR-206 antagomir and  
789 challenged with HDM or saline were calculated as described in Methods. (C) Counts for

790 macrophages, eosinophils, lymphocytes and neutrophils in BALF. (D) H&E staining of  
791 representative lung sections. (E) PAS staining for mucus in representative lung sections. (F) The  
792 numbers of PAS-staining-positive cells were counted in four random fields for each lung section at  
793  $\times 200$  magnification. (G-I) The protein levels of IL-4 (G), IL-5 (H), IL-13 (I) in BALF were  
794 determined by ELISA. (J) Plasma IgE levels in peripheral blood were determined by ELISA.  $n =$   
795 6-10 mice per group combined from 2 independent experiments. Data are mean  $\pm$  SD.  $*P < 0.05$ ;  
796  $**P < 0.01$ ;  $***P < 0.001$  (one-way ANOVA with Bonferroni's post hoc test). Scale bar =  $50\mu\text{m}$ .

797 **Figure 9. Perturbation of airway miR-206 expression alters HDM-induced Il-25, Il-33, Tslp**  
798 **expression and ILC2 expansion in mice lung.** (A-C) Il-25 (A), Il-33 (B) and Tslp (C) protein  
799 levels in BALF were determined by ELISA in mice intranasally administered with control or  
800 miR-206 antagomir and challenged with HDM or saline. (D-F) Il-25 (D), Il-33 (E) and Tslp  
801 protein levels (F) in BALF were determined by ELISA in mice intranasally administered with  
802 control or miR-206 agomir and challenged with HDM or saline.  $n =$  6-10 mice per group  
803 combined from 2 independent experiments. (G) Single cell suspensions of mouse lung tissue were  
804 incubated with cocktail of biotin-conjugated antibodies for lineage markers and mixed with  
805 Anti-Biotin MicroBeads to isolate lineage-negative lung cells. ILC2s in mice lungs were  
806 enumerated via flow cytometry analysis with lineage-negative lung cells using the following  
807 gating strategy: live, single,  $\text{CD}25^+$   $\text{CD}127^+$   $\text{ST}2^+$   $\text{Sca-1}^+$  cells. (H, J) Representative flow  
808 cytometric plots (H) and numbers of ILC2s (J) from lungs of mice intranasally administered with  
809 control or miR-206 antagomir and challenged with HDM or saline. (I, K) Representative flow  
810 cytometric plots (I) and numbers of ILC2s (K) from lungs of mice intranasally administered with  
811 control or miR-206 agomir and challenged with HDM or saline.  $n =$  4 -6 per group combined from

812 2 experiments. Data are mean  $\pm$  SD. \* $P$ <0.05; \*\* $P$ <0.01; \*\*\* $P$ <0.001 (one-way ANOVA with  
813 Bonferroni's post hoc test).

814 **Figure 10. Scheme for the signaling pathway regulating IL-25 and TSLP expression in**  
815 **airway epithelial cells in type 2-low and type 2-high asthma.** Allergen stimulates the rapid  
816 release of ATP from epithelial cells. Extracellular ATP serves as an alarmin to induce the  
817 expression of innate cytokines IL-25, TSLP. Meanwhile, acute accumulation of extracellular ATP  
818 decreases epithelial miR-206 expression, which upregulates CD39 expression to eliminate  
819 excessive ATP. Epithelial miR-206 is decreased in both type 2-low and type 2-high asthma.  
820 Compared with type 2-low asthma, less reduction of epithelial miR-206 resulted in higher  
821 miR-206, lower CD39 expression and impaired capacity to eliminate extracellular ATP in type  
822 2-high asthma. Consequently, more extracellular ATP is accumulated which leads to higher  
823 expression of IL-25, TSLP and more prominent type 2 inflammation in type 2-high asthma.

824

825

826

827 **Table 1. Subjects Characteristics\***

	Healthy control subjects	Type 2-low asthma patients	Type 2-high asthma patients	<i>p</i> value, type 2 low vs. high
Sample size, n	26	20	37	—
Age, yr	35.0 (28.8-42.3)	40.0 (32.3-49.5)	42.0 (31.5-50.0)	0.90
Sex, M:F (%F)	9:17 (65.3)	6:14 (70.0)	15:22 (59.5)	0.57
Body mass index	22.7 (20.6-23.8)	23.5 (21.4-25.3)	22.1 (20.6-24.0)	0.15
FEV <sub>1</sub> , % predicted	99.0 (96.0-105.7)	82.4 (68.8-90.2)	81.6 (71.4-88.2)	0.82
Methacholine PD <sub>20</sub> , mg	2.5 (2.5-2.5)	0.16 (0.04-0.25)	0.01 (0.01-0.05)	0.0009
Sputum eosinophil, %	0.3 (0-1.0)	1.8 (1.0-11.3)	16.0 (8.4-22.2)	0.0004
Blood eosinophil, ×10 <sup>9</sup> /L	0.06 (0.04-0.12)	0.12 (0.07-0.23)	0.33 (0.19-0.57)	0.0003
FeNO, ppb	14.0 (11.0-17.0)	32.8 (20.3-43.7)	94.7(65.0-134.6)	< 0.0001
Serum IgE, IU/ml	27.3 (16.9-41.3)	95.0 (11.9-187.0)	150.1(72.1-335.5)	0.03
Atopic, n (%)	3 (11.5)	18 (90.0)	37 (100.0)	0.12


828 \* Data are median (interquartile range) unless otherwise specified. *p* values comparing type 2-low with

829 type 2-high asthma were calculated by Fisher's exact test, or Mann-Whitney U test, as appropriate.


830 Definition of abbreviation: PD<sub>20</sub> = provocative dosage required to cause a 20% decline in FEV<sub>1</sub>. The

831 minimal and maximal provocative dosages were 0.01 and 2.505 mg, respectively.


832




**Figure 1. Epithelial miRNA expression profiling reveals differentially expressed miRNAs including miR-206 between type 2-low and –high asthma.** (A) Twenty differentially expressed epithelial miRNAs between subjects with type 2-low asthma (n = 4) and type 2-high asthma (n = 4) were identified using microarrays. Each column represents data from one subject. Colors represent fold change relative to the mean value of type 2-low asthma. (B) miR-206 transcript levels in bronchial brushings from type 2-low asthma patients (n = 20), type 2-high asthma patients (n = 37) and healthy controls (n = 26) were determined by quantitative PCR. The transcript levels are expressed as relative to the median value of healthy controls and log2 transformed. One-way ANOVA with Bonferroni's post hoc test was performed.




**Figure 2. The expression of CD39, a target of miR-206, is increased in airway epithelial cells in human asthma.** (A) The 3'-UTR of CD39 contains region that matches the seed sequence of hsa-miR-206. (B) 3'-UTR luciferase report assay with vector harboring wild-type (WT), mutant CD39 3'-UTR or no 3'-UTR (control) co-transfected with miR-206 mimic or non-targeting control. Luciferase activity was measured by dual-luciferase reporter assay system. The firefly luciferase activity was normalized to renilla luciferase activity.  $n = 4$  per group. (C, D) CD39 transcript levels in BEAS-2B cells after transfection with miR-206 mimic (C) or inhibitor (D) were determined by quantitative PCR. The transcript levels are expressed as relative to the mean value of controls (two-tailed Student's  $t$  test).  $n = 4$  per group. Data are mean  $\pm$  SD. (E) CD39 protein expression in BEAS-2B cells after transfection with miR-206 mimic and inhibitor were determined by Western blotting. (F) CD39 transcript levels in bronchial brushings from type 2-low asthma patients ( $n = 20$ ), type 2-high asthma patients ( $n=37$ ) and healthy controls ( $n = 26$ ) were determined by quantitative PCR. The transcript levels are expressed as relative to the median value of controls and log<sub>2</sub> transformed (one-way ANOVA with Bonferroni's post hoc test). (G) Spearman's rank order correlation assay between epithelial CD39 and miR-206 transcript levels in all asthma patients ( $n = 57$ ).




**Figure 3. Acute extracellular ATP accumulation is responsible for allergen-induced miR-206 downregulation and CD39 upregulation in bronchial epithelial cells.** (A) ATP levels in BALF from type 2-low asthma patients ( $n = 20$ ), type 2-high asthma patients ( $n = 37$ ), and healthy controls ( $n = 26$ ) were determined by luciferase bioluminescence. BALF ATP levels were expressed as luminometer counts (one-way ANOVA with Bonferroni's post hoc test). (B) ATP concentration in culture medium collected at indicated time points after HDM stimulation was measured by luciferase bioluminescence. (C, D) Transcript levels of miR-206 (C) and CD39 (D) in HBE cells harvested at indicated time points after HDM stimulation were determined by quantitative PCR.  $n = 4-6$  per time point combined from 2 experiments using HBE cells from 2 healthy donors. Data are mean  $\pm$  SD. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  (one-way ANOVA with Bonferroni's post hoc test). (E-F) MiR-206 transcript levels in HBE cells pretreated with apyrase or saline for 2 h before adding HDM and stimulation for 6 h (E), and treated with ATP $\gamma$ S or saline with or without HDM for 6h (F). (G, H) CD39 transcript levels in HBE cells pretreated with apyrase or saline for 2 h before adding HDM and stimulation for 6 h (G), and treated with ATP $\gamma$ S or saline with or without HDM for 6h (H). The transcript levels are expressed as relative to the mean value of control group and log2 transformed.  $n = 4-6$  wells per group combined from 2 experiments using HBE cells from 2 healthy donors. Data are mean  $\pm$  SD. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  (one-way ANOVA with Bonferroni's post hoc test).




**Figure 4. Airway IL-25 and TSLP expression is elevated in type 2-high asthma, and correlates with BALF ATP levels in asthma.** (A-C) The transcripts of *IL-25* (A), *IL-33* without exons 3, 4 (B), and long isoform of *TSLP* (C) in bronchial epithelial brushings from type 2-low asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using quantitative PCR with Taqman primers and probes. For detection of *IL-33* transcript without exons 3 and 4, RNase H-dependent quantitative PCR was performed. The transcript levels are expressed as relative to the median value of healthy controls and log2 transformed. (D-F) IL-25 (D), IL-33 (E) and TSLP (F) protein levels in BALF from type 2-low asthma (n = 20), type 2-high asthma (n = 37) and healthy controls (n = 26) were determined using ELISA. One-way ANOVA with Bonferroni's post hoc test was performed. (G-H) Spearman's rank order correlation assays between BALF ATP levels and BALF IL-25 protein levels (G), and TSLP protein levels (H).






**Figure 6. MiR-206 regulates allergen-induced IL-25 and TSLP expression via targeting CD39**


**- extracellular ATP axis in bronchial epithelial cells.** (A) CD39 transcript levels in HBE cells transfected with control or miR-206 inhibitor and stimulated with or without HDM for 6 h were determined by quantitative PCR. (B) ATP concentration in culture medium after transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (C, D) IL-25 (C), and TSLP (D) protein levels in culture medium after transfection with control or miR-206 inhibitor and stimulation with or without HDM for 6 h were determined by ELISA. (E) CD39 transcript levels in HBE cells transfected with control or miR-206 mimic and stimulated with or without HDM for 6 h were determined by quantitative PCR. (F) ATP concentration in culture medium after transfection with control or miR-206 mimic and stimulation with or without HDM for 6 h were measured by luciferase bioluminescence. (G, H) IL-25 (G), and TSLP (H) protein levels in culture medium after transfection with control or miR-206 mimic and stimulation with or without HDM for 6 h were determined by ELISA. n = 4 wells per group. Data are mean ± SD. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  (one-way ANOVA with Bonferroni's post hoc test). n = 5-6 wells per group combined from 2 experiments using HBE cells from 2 healthy donors.



**Figure 7. Epithelial miR-206 targets CD39-extracellular ATP axis in a murine model of allergic airway inflammation.** (A) Experimental schedule as described in Methods. (B-D) MiR-206 (B) and CD39 (C) transcript levels in lungs, and ATP levels in BALF (D) were determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally administered with control or miR-206 antagonist and challenged with HDM or saline. (E-G) MiR-206 (E) and CD39 (F) transcript levels in lungs, and ATP levels in BALF (G) were determined by quantitative PCR and luciferase bioluminescence, respectively, in mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline. The transcript level is expressed relative to the mean value of control group and log<sub>2</sub> transformed. BALF ATP levels were expressed as luminometer counts. n = 6 - 10 mice per group combined from 2 independent experiments. Data are mean ± SD. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001 (one-way ANOVA with Bonferroni's post hoc test). (H, I) Representative images of *in situ* hybridization of miR-206 (H), and immunohistochemistry of CD39 (I) in lung sections of mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline. Scale bar = 50 μm.




**Figure 8. Airway miR-206 antagonism suppresses HDM-induced AHR, airway inflammation, mucus overproduction and type 2 response in mice.** (A) Respiratory resistance in response to different concentration of intravenous acetylcholine at 24 h after the last HDM or saline challenge in mice intranasally administered with control or miR-206 antagonir. (B) Inflammatory scores of lung sections from mice intranasally administered with control or miR-206 antagonir and challenged with HDM or saline were calculated as described in Methods. (C) Counts for macrophages, eosinophils, lymphocytes and neutrophils in BALF. (D) H&E staining of representative lung sections. (E) PAS staining for mucus in representative lung sections. (F) The numbers of PAS-staining-positive cells were counted in four random fields for each lung section at ×200 magnification. (G-I) The protein levels of IL-4 (G), IL-5 (H), IL-13 (I) in BALF were determined by ELISA. (J) Plasma IgE levels in peripheral blood were determined by ELISA. n = 6-10 mice per group combined from 2 independent experiments. Data are mean ± SD. \**P*<0.05; \*\**P*<0.01; \*\*\**P*<0.001 (one-way ANOVA with Bonferroni's post hoc test). Scale bar = 50 μm.



**Figure 9. Perturbation of airway miR-206 expression alters HDM-induced IL-25, IL-33, Tslp expression and ILC2 expansion in mice lung.**

(A-C) IL-25 (A), IL-33 (B) and Tslp (C) protein levels in BALF were determined by ELISA in mice intranasally administered with control or miR-206 antagonist and challenged with HDM or saline. (D-F) IL-25 (D), IL-33 (E) and Tslp protein levels (F) in BALF were determined by ELISA in mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline.  $n = 6-10$  mice per group combined from 2 independent experiments. (G) Single cell suspensions of mouse lung tissue were incubated with cocktail of biotin-conjugated antibodies for lineage markers and mixed with Anti-Biotin MicroBeads to isolate lineage-negative lung cells. ILC2s in mice lungs were enumerated via flow cytometry analysis with lineage-negative lung cells using the following gating strategy: live, single, CD25<sup>+</sup> CD127<sup>+</sup> ST2<sup>+</sup> Sca-1<sup>+</sup> cells. (H, J) Representative flow cytometric plots (H) and numbers of ILC2s (J) from lungs of mice intranasally administered with control or miR-206 antagonist and challenged with HDM or saline. (I, K) Representative flow cytometric plots (I) and numbers of ILC2s (K) from lungs of mice intranasally administered with control or miR-206 agomir and challenged with HDM or saline.  $n = 4-6$  per group combined from 2 experiments. Data are mean  $\pm$  SD. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  (one-way ANOVA with Bonferroni's post hoc test).



**Figure 10. Scheme for the signaling pathway regulating IL-25 and TSLP expression in airway epithelial cells in type 2-low and type 2-high asthma.** Allergen stimulates the rapid release of ATP from epithelial cells. Extracellular ATP serves as an alarmin to induce the expression of innate cytokines IL-25, TSLP. Meanwhile, acute accumulation of extracellular ATP decreases epithelial miR-206 expression, which upregulates CD39 expression to eliminate excessive ATP. Epithelial miR-206 is decreased in both type 2-low and type 2-high asthma. Compared with type 2-low asthma, less reduction of epithelial miR-206 resulted in higher miR-206, lower CD39 expression and impaired capacity to eliminate extracellular ATP in type 2-high asthma. Consequently, more extracellular ATP is accumulated which leads to higher expression of IL-25, TSLP and more prominent type 2 inflammation in type 2-high asthma.